By assessing the differential GLUT expression in cancer and immune cells, we investigated whether GLUT expression levels can be used as a biomarker to uncover immune functionality in TME using melanoma cohorts who underwent immunotherapy. This evidence concerns the gene SLC2A1 and cancer.